Cheilbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 03:33 am EST
Share
Cheilbio Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 3,858.54 million compared to KRW 3,409.61 million a year ago. Net loss was KRW 344.18 million compared to KRW 122.55 million a year ago. Basic loss per share from continuing operations was KRW 14 compared to KRW 4 a year ago. Basic loss per share was KRW 14 compared to KRW 4 a year ago.
For the nine months, sales was KRW 11,573.7 million compared to KRW 12,694.7 million a year ago. Net loss was KRW 1,783.37 million compared to net income of KRW 1,637.22 million a year ago. Basic loss per share from continuing operations was KRW 65 compared to basic earnings per share from continuing operations of KRW 58 a year ago. Basic loss per share was KRW 65 compared to basic earnings per share of KRW 58 a year ago.
Cheilbio Co., Ltd. is a Korea-based company engaged in the manufacturing of veterinary drugs. The Company's offerings consist of antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, diagnostic kits including enzyme-linked immunosorbent assay (ELISA) test kits, virus test kits and deoxyribonucleic acid (DNA) kits, as well as feed additives. The Companyâs products are used for cattle, pigs, chickens, pets and other animals. It supplies its products mainly to the domestic market.
CHEILBIO CO., LTD. 
